Future growth expectations in sales/revenue/volumes?

SteriPort line commissioning expected by June 20, 2026, adding INR 80-85 crore in revenue for FY27 (three quarters), with full INR 110-120 crore impact in FY28. New product pipeline of 20 products in inhalation and ophthalmic segments to commercialize in FY27-28, supporting growth. Export revenue grew from 32% in FY25 to 39% in FY26; active marketing in 25-30 countries with key markets including UK, Thailand, Philippines, South Sudan. Export markets like East Africa show cyclical buying patterns; export sales generally stronger in H2. Domestic IV fluid demand growing at 8-10% year-on-year, wit

Future growth expectations in earnings/operating earnings/profits/EPS?

FY26 PAT margin stood at 5%, with PAT growing 42% YoY, supported by better operating leverage and reduced finance cost. SteriPort expansion expected to increase EBITDA margin from 22% to around 24-25% with a 27% EBITDA margin from the new SteriPort line. SteriPort line commissioning by June-end, expected contribution of INR 80-85 crores revenue in FY27 (three quarters), with full impact INR 110-120 crores in FY28. PAT margin of 5-6% sustainable short-term; expected to improve by at least 3% post-leveraging. Growth driven by expanding higher-value product lines like SteriPort, inhalation soluti

Current/ Expected Orderbook/ Pending Orders?

Amanta Healthcare Limited does not maintain a long-term order book extending over one year. Export orders are rolling and cyclic, with visibility of around 3 to 6 months in some markets. For example, the East African market's significant purchases happen from September to March, and export numbers tend to be better in H2 than H1. Markets like Southeast Asia show consistent order patterns throughout the year. The management currently does not have exact quantified numbers for the next quarter's order book but may share it separately. The company operates primarily on distributor-based orders ra

IN US

Sale is live|00:00:00left today

Amanta Healthcare LtdQ1 FY26Pharmaceuticals & Biotechnology

Amanta Healthcare Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹161P/E: 31.5Market Cap: ₹503 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→SteriPort line commissioning expected by June 20, 2026, adding INR 80-85 crore in revenue for FY27 (three quarters), with full INR 110-120 crore impact in FY28.
→New product pipeline of 20 products in inhalation and ophthalmic segments to commercialize in FY27-28, supporting growth.
→Export revenue grew from 32% in FY25 to 39% in FY26; active marketing in 25-30 countries with key markets including UK, Thailand, Philippines, South Sudan.
→Export markets like East Africa show cyclical buying patterns; export sales generally stronger in H2.
→Domestic IV fluid demand growing at 8-10% year-on-year, with two-port systems growing faster at 12-13%.
→Capacity ramp-up expected to reach full utilization within 3-4 months post commissioning, driving scale and margin expansion.
→Solar power project to reduce costs and boost profitability from FY27 onwards.
→Overall, growth driven by capacity expansion, new specialized products, and export market expansion.

Margin guidance

Category 3

→FY26 PAT margin stood at 5%, with PAT growing 42% YoY, supported by better operating leverage and reduced finance cost.
→SteriPort expansion expected to increase EBITDA margin from 22% to around 24-25% with a 27% EBITDA margin from the new SteriPort line.
→SteriPort line commissioning by June-end, expected contribution of INR 80-85 crores revenue in FY27 (three quarters), with full impact INR 110-120 crores in FY28.
→PAT margin of 5-6% sustainable short-term; expected to improve by at least 3% post-leveraging.
→Growth driven by expanding higher-value product lines like SteriPort, inhalation solutions, and ophthalmic products with 20 products in pipeline.
→Lower finance cost due to debt refinancing and repayment expected to disproportionately boost PAT growth versus EBITDA.
→Overall, steady revenue growth, margin expansion, and improved profitability projected through product portfolio and capacity expansions.

3 more insights locked — sign up free to unlock

Fundraise plans

- The company has recently completed a refinancing exercise post-IPO, replacing higher-cost debt with lower-cost borrowings, resulting in a significant reduction in finance cost. - Currently, about 90% of the company's borrowings are at single-digit interest rates. - The total debt as of March 26 was INR 234 crore, which has reduced to INR 204 crore in early April after repayment. - Management expects to further replace around INR 30 crore to INR 40 crore of existing debt with cheaper debt within the next six months. - There is no mention of any ongoing or planned equity fundraising. - The company remains focused on maintaining a disciplined balance sheet while investing for long-term growth. Hence, while the company is actively managing and reducing its debt cost, no specific new debt or equity fundraising is announced or planned immediately.

Order book

→Amanta Healthcare Limited does not maintain a long-term order book extending over one year.
→Export orders are rolling and cyclic, with visibility of around 3 to 6 months in some markets.
→For example, the East African market's significant purchases happen from September to March, and export numbers tend to be better in H2 than H1.
→Markets like Southeast Asia show consistent order patterns throughout the year.
→The management currently does not have exact quantified numbers for the next quarter's order book but may share it separately.
→The company operates primarily on distributor-based orders rather than fixed long-term contracts.

Capex plans

Yes

- SteriPort expansion: Commissioning expected by June 2026, aiming for operational by June 20; will add approx. INR110-120 crore top line from FY27 onwards with EBITDA margin around 27%. - SVP (Small Volume Parenteral) line: To be commissioned in late 2026 (October-December), focusing on inhalation and ophthalmic product pipelines, expected commercialization in FY27-28. - Solar power project: 10.8 MW captive solar plant to be commissioned by May 2026, expected to reduce power costs by about INR75 lakh per month starting FY27, improving cost efficiency and ESG profile. - Product pipeline: Currently developing 20 products primarily in inhalation and ophthalmic segments to enhance higher-margin and specialized products. - Focus on regulatory approvals and portfolio expansion to enter regulated markets alongside semi-regulated and emerging markets. These strategic investments aim to drive revenue growth, margin expansion, and operational efficiencies in upcoming years.

How does Amanta Healthcare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Amanta Healthcare Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Amanta Healthcare Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio